Acetylation at residue K280 (Lys280) showed a distinctly pathological signature marking mature tau lesions in Alzheimer’s disease (AD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and several FTDP-17 familial cases of dementia [3] but was rarely observed in control brain tissue or cultured wild-type cells or neurons [4], illustrating the disease-specific nature of K280 acetylation. Here, MAPT is linked to Alzheimer disease.